PMV Pharmaceuticals Inc. (PMVP): Price and Financial Metrics
GET POWR RATINGS... FREE!
PMVP Stock Price Chart Interactive Chart >
PMVP Price/Volume Stats
| Current price | $15.00 | 52-week high | $37.32 |
| Prev. close | $14.22 | 52-week low | $11.44 |
| Day low | $13.77 | Volume | 970,900 |
| Day high | $15.17 | Avg. volume | 879,566 |
| 50-day MA | $17.19 | Dividend yield | N/A |
| 200-day MA | $21.90 | Market Cap | 683.61M |
PMV Pharmaceuticals Inc. (PMVP) Company Bio
PMV Pharmaceuticals, Inc., a precision oncology company, discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. Its lead product candidate is PC14586, a small molecule that corrects and restores p53 function. The company also develops product candidates for p53 R273H hotspot mutation and other p53 hotspot mutations. PMV Pharmaceuticals, Inc. was formerly known as PJ Pharmaceuticals, Inc. and changed to in July 2013. The company was founded in 2013 and is headquartered in Cranbury, New Jersey.
Latest PMVP News From Around the Web
Below are the latest news stories about PMV Pharmaceuticals Inc that investors may wish to consider to help them evaluate PMVP as an investment opportunity.
PMV Pharmaceuticals to Participate in the Guggenheim Healthcare Talks 2022 Oncology DayCRANBURY, N.J., Feb. 03, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that David H. Mack, Ph.D., President & Chief Executive Officer, will represent PMV Pharmaceuticals in a “Fireside Chat” at the Guggenheim Healthcare Talks 2022 Oncology Day taking place on February 9, 2022. The company will also participate in one-on-one |
Thinking about buying stock in Nextplay Technologies, Vinco Ventures, Orchid Island Capital, Altria Group, or PMV Pharmaceuticals?NEW YORK , Jan. 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NXTP, BBIG, ORC, MO, and PMVP. Full story available on Benzinga.com |
Do Hedge Funds Love PMV Pharmaceuticals, Inc. (PMVP)?We at Insider Monkey have gone over 867 13F filings that hedge funds and prominent investors are required to file by the SEC. |
PMV Pharma Announces Changes to its Board of DirectorsCRANBURY, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations, today announced the appointment of Kirsten Flowers to its Board of Directors. Concurrent with the appointment of Ms. Flowers, Peter Thompson, M.D. will resign from PMV’s Board. “Peter has been an invaluable member of the Board during a period of substantial growth and |
We're Hopeful That PMV Pharmaceuticals (NASDAQ:PMVP) Will Use Its Cash WiselyJust because a business does not make any money, does not mean that the stock will go down. For example, although... |
PMVP Price Returns
| 1-mo | -6.25% |
| 3-mo | -1.57% |
| 6-mo | -37.42% |
| 1-year | -58.10% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -35.06% |
| 2021 | -62.45% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...